An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Inclusion Criteria

• •1. Subject is aged 18 to 65 years, at time of enrollment into the preceding acute study (KAR-007/009).
• •2. Subject is capable of providing informed consent.
• •1. A signed informed consent form must be provided before any study assessments are performed.
• •2. Subject must be fluent in (oral and written) English (United States only) or local language (Ukraine only) to consent.
• •3. Subject has completed the treatment period on study drug (through Day 35 -2 days) of Studies KAR-007 or KAR-009.
• •4. Subject resides in a stable living situation, in the opinion of the investigator.
• •5. Subject has an identified, reliable informant/caregiver willing to be able to address some questions related to certain study visits, if needed. An informant/caregiver may not be necessary if the subject has been the patient of the investigator for ≥1 year.
• •6. Women of childbearing potential or men with sexual partners of childbearing potential must be sexually abstinent (in line with their preferred and usual lifestyle) or willing and able to use at least 1 highly effective method of contraception during the study and for at least 7 days after the last dose of KarXT. Sperm donation is not allowed for 7 days after the final dose of KarXT.